Rhumbline Advisers Editas Medicine, Inc. Transaction History
Rhumbline Advisers
- $109 Billion
- Q4 2024
A detailed history of Rhumbline Advisers transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 140,717 shares of EDIT stock, worth $242,033. This represents 0.0% of its overall portfolio holdings.
Number of Shares
140,717
Previous 141,875
0.82%
Holding current value
$242,033
Previous $483,000
63.15%
% of portfolio
0.0%
Previous 0.0%
Shares
29 transactions
Others Institutions Holding EDIT
# of Institutions
227Shares Held
54.2MCall Options Held
412KPut Options Held
355K-
Black Rock Inc. New York, NY7.78MShares$13.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.82MShares$11.7 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.75MShares$4.72 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.16MShares$3.71 Million0.0% of portfolio
-
State Street Corp Boston, MA1.87MShares$3.22 Million0.0% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $118M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...